Uncertainty About the Benefits of New Cancer Drugs and Patients' Treatment Preferences

Sponsor
London School of Economics and Political Science
Study ID
NCT07694310
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Control — OTHER
    No uncertainty information
  • Unvalidates surrogate endpoint — OTHER
    Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live.
  • Limited study population — OTHER
    Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her.
  • Small magnitude of effect — OTHER
    It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.
  • Multiple uncertainties — OTHER
    All 3 statements shown above

Study Details

This study of current or former cancer patients will evaluate the effect of learning about uncertainties with the benefits of a new cancer drug on their hypothetical decisions to take the drug and their perceptions of the drug's effectiveness.

Key Dates

First listed
Jul 9, 2026
Start date
Jul 14, 2026
Status verified
Jun 2026
Primary completion
Oct 1, 2026
Completion
Oct 1, 2026

Study Design

Enrollment
3,000 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Placebo Comparator: Control
    No uncertainty information
  • Active Comparator: Unvalidated surrogate endpoint
    Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live.
  • Active Comparator: Limited study population
    Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her.
  • Active Comparator: Small magnitude of effect
    It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.
  • Active Comparator: Multiple uncertainties
    All 3 statements shown above

Primary Outcome Measure

Hypothetical decisions [ Time Frame: Assessed immediately after the intervention ]

Central Contacts

Related Studies